Currently Viewing:
Newsroom
Currently Reading
Older Age May Improve Immunotherapy Outcomes in Melanoma
December 07, 2017 – Surabhi Dangi-Garimella, PhD
Scientists Discover Gene That May Cause Melanoma to Metastasize
December 05, 2017 – Samantha DiGrande
NCI Expands Clinical Trial Access for Patients With HIV in CITN-12 Trial
December 04, 2017 – Jaime Rosenberg
How Smartphone Cameras Can Lead to Pediatric Dermatology Diagnosis
November 30, 2017 – Samantha DiGrande
Pembrolizumab Shows Promise for Advanced Esophageal Cancer
November 30, 2017 – Allison Inserro
Single-Agent Ipilimumab Ineffective in HPV-Related Advanced Cervical Cancer
November 29, 2017 – Surabhi Dangi-Garimella, PhD
Review Finds Strong Association Between Atopic Dermatitis and Occupational Hand Eczema
November 29, 2017 – Samantha DiGrande
Consequences and Outcomes of Consolidation in Dermatology Driven by Private Investors
November 22, 2017 – AJMC Staff
A New Target for CAR T Cells Achieves Remission in Resistant Pediatric B-ALL
November 21, 2017 – Surabhi Dangi-Garimella, PhD

Older Age May Improve Immunotherapy Outcomes in Melanoma

Surabhi Dangi-Garimella, PhD
According to a new study published in JAMA Dermatology, older patients had better clinical outcomes than their younger comparator cohort following treatment with newer immunotherapy agents for their advanced melanoma.
According to a new study published in JAMA Dermatology, older patients had better clinical outcomes than their younger comparator cohort following treatment with newer immunotherapy agents for their advanced melanoma.

The single-center retrospective study in France included 92 patients who received treatment for their advanced melanoma in the Lyon Sud Hospital between January 2007 and February 2016. Treating agents include ipilimumab (a cytotoxic T-lymphocyte–associated antigen 4 inhibitor), nivolumab (a programmed cell death-1, PD-1, inhibitor), or pembrolizumab (a programmed death ligand-1 inhibitor), for a total of 120 lines of treatment.

Nearly 60% of patients were 65 years or younger (24 [44%] were female; mean [SD] age, 48.1 [12.5] years) and the remaining 38 were over 65 years (12 [34%] were female; mean [SD] age, 74.8 [6.9] years). The mean duration of follow-up was 12.5 months at treatment initiation.

The authors found that progression-free survival (PFS) was better in the older population: mean PFS was determined to be 4.8 months in the older cohort, compared with 3.4 months in the younger cohort (P = .04) following univariate analysis. Additionally, while overall survival (OS) had not been reached in the older population at the time of analysis, the mean OS in the younger cohort was 10.1 months (P = .009). This was more obvious in the patients who were treated with the PD-1 inhibitor, nivolumab.

With respect to immune-related adverse (irAEs) events, which are commonly observed with these agents, the authors did not observe any difference in the most common irAEs between the 2 cohorts, although older patients had more comorbidities. However, older patients more frequently developed meningitis and immunologic nephritis. 

“Age might be associated with a better clinical outcome after treatment with immunotherapy in the real-life setting,” the authors write. They do, however, recommend the need for additional studies to confirm their findings

Reference

Perier-Muzet M, Gatt E, Péron J, et al. Association of immunotherapy with overall survival in elderly patients with melanoma [published online December 6, 2017]. JAMA Dermatol. doi:10.1001/jamadermatol.2017.4584.

 
Copyright AJMC 2006-2019 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
x
Welcome the the new and improved AJMC.com, the premier managed market network. Tell us about yourself so that we can serve you better.
Sign Up